About MYOS RENS Technology
MYOS RENS Technology Inc. (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity. The Company is focused on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining the health and performance of muscle tissue. MYOS is evaluating the modulation of myostatin. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: MYOS
- CUSIP:
Key Metrics:
- Previous Close: $1.75
- 50 Day Moving Average: $1.70
- 200 Day Moving Average: $1.80
- 52-Week Range: $1.23 - $4.40
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Market Cap: $8.89M
- Outstanding Shares: 5,081,000
- Beta: 1.21
Additional Links:
Companies Related to MYOS RENS Technology:
Consensus Ratings for MYOS RENS Technology (NASDAQ:MYOS) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for MYOS RENS Technology (NASDAQ:MYOS)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for MYOS RENS Technology (NASDAQ:MYOS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2015 | | | | | | | | |
| 11/17/2014 | | ($0.24) | ($0.73) | | | View | N/A |  |
| 8/14/2014 | Q214 | ($0.20) | ($0.34) | | $1.68 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for MYOS RENS Technology (NASDAQ:MYOS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for MYOS RENS Technology (NASDAQ:MYOS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for MYOS RENS Technology (NASDAQ:MYOS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/23/2016 | Zhengguang Lyu | Director | Buy | 50,000 | $1.70 | $85,000.00 | |
| 9/6/2016 | Zhengguang Lyu | Director | Buy | 23,505 | $1.60 | $37,608.00 | |
| 6/17/2016 | Zhengguang Lyu | Director | Buy | 10,000 | $1.65 | $16,500.00 | |
| 4/8/2016 | Joseph Mannello | Director | Buy | 4,417 | $1.96 | $8,657.32 | |
| 4/5/2016 | Joseph Mannello | Director | Buy | 6,128 | $1.75 | $10,724.00 | |
| 9/29/2015 | Robert J. Hariri | Director | Buy | 2,300 | $2.68 | $6,164.00 | |
| 9/25/2015 | Robert J. Hariri | Director | Buy | 12,150 | $2.44 | $29,646.00 | |
| 9/11/2015 | Robert J. Hariri | Director | Buy | 4,000 | $1.73 | $6,920.00 | |
| 9/8/2015 | Robert J. Hariri | Director | Buy | 25,250 | $1.71 | $43,177.50 | |
| 9/4/2015 | Louis J Aronne | Director | Buy | 5,000 | $1.76 | $8,800.00 | |
| 8/28/2015 | Robert J Hariri | Director | Buy | 2,750 | $1.74 | $4,785.00 | |
| 12/4/2014 | Robert J Hariri | Director | Buy | 2,200 | $8.16 | $17,952.00 | |
| 8/18/2014 | Peter Diamandis | Director | Buy | 3,444 | $14.51 | $49,972.44 | |
(Data available from 1/1/2013 forward)
Latest Headlines for MYOS RENS Technology (NASDAQ:MYOS)| Date | Headline |
|---|
 | MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer (NASDAQ:MYOS)
www.publicnow.com - September 27 at 10:53 AM |
 | MYOS RENS Tech appoints interim CEO (NASDAQ:MYOS)
www.njbiz.com - September 8 at 6:05 PM |
| Report explores the 2016 H2 sarcopenia pipeline market outlook research (NASDAQ:MYOS)
www.whatech.com - September 2 at 11:09 AM |
 | BRIEF-Myos Rens Technology appoints Joseph Mannello interim CEO (NASDAQ:MYOS)
www.reuters.com - August 31 at 11:21 AM |
 | MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events (NASDAQ:MYOS)
biz.yahoo.com - August 24 at 6:07 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MYOS)
biz.yahoo.com - June 29 at 4:17 PM |
 | MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 (NASDAQ:MYOS)
www.capitalcube.com - June 22 at 11:58 AM |
| FDA approves minimally invasive AspireAssist weight loss device (NASDAQ:MYOS)
www.healio.com - June 16 at 10:36 AM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant (NASDAQ:MYOS)
biz.yahoo.com - May 20 at 5:26 PM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:MYOS)
biz.yahoo.com - May 13 at 8:34 AM |
| MYOS Reports Positive Results From Fortetropin(R) Clinical Study (NASDAQ:MYOS)
finance.yahoo.com - April 22 at 3:00 PM |
| MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q4, 2015 By the Numbers (NASDAQ:MYOS)
www.capitalcube.com - April 11 at 8:51 AM |
| MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: 2015 By the Numbers (NASDAQ:MYOS)
www.capitalcube.com - April 11 at 7:49 AM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 10-K, Annual Report (NASDAQ:MYOS)
biz.yahoo.com - March 30 at 5:53 PM |
| MYOS Corporation Announces Corporate Name Change to MYOS RENS Technology Inc. (NASDAQ:MYOS)
www.publicnow.com - March 23 at 5:21 AM |
| MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ (NASDAQ:MYOS)
biz.yahoo.com - March 22 at 4:33 PM |
| MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Cha (NASDAQ:MYOS)
biz.yahoo.com - March 8 at 5:31 PM |
| MYOS Corporation Announces Election of New Directors and Appointment of Ren Ren as Global Chairman (NASDAQ:MYOS)
finance.yahoo.com - March 8 at 4:17 PM |
| Rheumatoid arthritis market pipeline review H2 2015 published by leading research firm (NASDAQ:MYOS)
www.whatech.com - February 12 at 2:47 PM |
| MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events (NASDAQ:MYOS)
biz.yahoo.com - February 4 at 5:21 PM |
| MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation o (NASDAQ:MYOS)
biz.yahoo.com - December 22 at 5:09 PM |
| MYOS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters (NASDAQ:MYOS)
biz.yahoo.com - December 21 at 4:32 PM |
 | Why Are These Stocks Gaining Ground on Thursday? (NASDAQ:MYOS)
www.insidermonkey.com - December 17 at 1:55 PM |
 | MYOS Corporation Announces Strategic Investment by RENS Technology Inc. (NASDAQ:MYOS)
www.noodls.com - December 17 at 8:16 AM |
| MYOS CORP Financials (NASDAQ:MYOS)
finance.yahoo.com - December 8 at 1:18 PM |
| MYOS CORP Files SEC form 8-K, Other Events (NASDAQ:MYOS)
biz.yahoo.com - November 30 at 5:21 PM |
| MYOS CORP Files SEC form 10-Q, Quarterly Report (NASDAQ:MYOS)
biz.yahoo.com - November 16 at 5:15 PM |
| MYOS Corp. – Value Analysis (NASDAQ:MYOS) : November 3, 2015 (NASDAQ:MYOS)
www.capitalcube.com - November 3 at 12:08 PM |
| Maintaining Muscle Linked to Preserving Healthy Brain Tissue (NASDAQ:MYOS)
www.noodls.com - October 26 at 7:55 AM |
| MYOS' Proprietary Muscle Building Technology Fortetropin: Foundation for New Dietary Recommendations (NASDAQ:MYOS)
www.noodls.com - October 19 at 7:51 AM |
| MYOS Corp. Earnings Q2, 2015 (NASDAQ:MYOS)
www.capitalcube.com - October 2 at 10:53 AM |
MYOS RENS Technology (NASDAQ:MYOS) Chart for Wednesday, September, 28, 2016
